目的：观察柔肝降酶合剂治疗四氯化碳（CCl4）所致大鼠急性肝损伤的效果。方法：SD 雄性大鼠60 只，随机分成6 组，分别为柔肝降酶合剂低、中、高3 个剂量组、葡醛内酯组、正常组及模型组，采用CCl4 腹腔注射致大鼠急性肝损伤模型，各中药组每日灌胃柔肝降酶合剂，正常组和模型组给予蒸馏水灌胃，葡醛内酯组灌胃葡醛内酯水溶液，于实验的第12 天，禁食16 澡后处死大鼠，检查肝组织病理学改变，测定大鼠血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST），肝组织匀浆测定大鼠肝组织超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、还原型谷胱甘肽（GSH）、过氧化氢酶（CAT）及丙二醛（MDA），RT-PCR 法检测大鼠肝脏血红素氧化酶（HO-1）mRNA 表达水平。结果：与模型组比较，柔肝降酶合剂各剂量组大鼠肝病理损害均不同程度减轻，柔肝降酶合剂各剂量组及葡醛内酯组血清ALT 及AST含量均明显降低（P＜0.05 或P＜0.01）；柔肝降酶合剂各剂量组、葡醛内酯组肝匀浆GSH、GSH-Px、CAT、SOD 含量明显升高（P＜0.05 或P＜0.01），MDA 含量明显降低（P约0.05 或P约0.01）；各治疗组肝脏HO-1 mRNA 相对表达量明显升高（P＜0.05 或P＜0.01）。结论：柔肝降酶合剂防治CCl4 所致大鼠急性肝损伤疗效确切。

This study was aimed to observe the effect of Softening Liver and Reducing Enzyme Mixed Agent (SLREXA) in the prevention of acute liver injury rats induced by carbon tetrachloride (CCl4). A total of 60 male SD rats were randomly divided into 6 groups, which were the SLREXA low-, middle-, high-dose group, glucurolactone group, normal group and model group. Intraperitoneal injection of CCl4 was used to induce acute liver injury rat model. Intragastric administration of SLREXA was given to each Chinese medicine group. Intragastric administration of distilled water was given to the normal group and the model group. Intragastric administration of glucurolactone aqueous solution was given to the glucurolactone group. On the 12th day of the experiment, after 16-hour fasting, rats were killed. Pathological changes in liver tissues were examined. Blood serum was determined for alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The liver homogenate was determined for superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione (GSH), catalase (CAT) and malondialdehyde (MDA) in liver tissues of rats. RT-PCR was used to detect the expression level of mRNA in liver heme oxygenase-1 (HO-1). The results showed that in the microscopic examination of liver tissues, compared with the model group, different doses of SLREXA can alleviate pathological damages of liver in varying degrees. Levels of blood serum ALT and AST content in different doses of SLREXA groups and glucurolactone group were significantly lower than those of the model group (P < 0.05 or P < 0.01). Compared with the model group, contents of GSH-Px, GSH, SOD, CAT in the liver homogenate were significantly increased, and MDA content was decreased significantly (P < 0.05 or P < 0.01) in different doses of SLREXA groups and glucurolactone group; compared with the model group, the HO-1 mRNA relative expression quantity in the normal group and each treatment group increased obviously, with statistical significance (P< 0.05 or P < 0.01). It was concluded that SLREXA can prevent CCl4-induced liver injury rats with definite therapeutic effect.

恩施土家族苗族自治州科技局指导项目（EK20120013）：柔肝降酶合剂抗药物性肝损伤的临床与实验研究，负责人：陈普艳。